Revlimid® as Consolidation Treatment Chronic Lymphocytic Leukemia

Inclusion Criteria: * Diagnosis of chronic lymphocytic leukemia: * Previously treated patients of any age with a diagnosis of CLL with documented residual disease following therapy, but not meeting an indication for treatment based on current guidelines * At least 2 months following previous CLL directed therapy * ECOG performance status of less than or equal to 2 at study entry * Laboratory test results within these ranges: * Platelet count greater than or equal to 50 x 109/L * CrCl \>.60 ml/min * Total bilirubin less than or equal to 1.5 mg/dL * AST (SGOT) and ALT (SGPT) less than or equal to 2 x ULN * Females of childbearing must adhere to strict guidelines and have negative pregnancy test prior to enrollment * Understand and voluntarily sign an informed consent form. * Age greater than or equal to 18 years at the time of signing the informed consent form. * Able to adhere to the study visit schedule and other protocol requirements. * Disease free of prior malignancies for greater than or equal to 2 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma in situ" of the cervix or breast. * All study participants must be registered into the mandatory RevAssist® program, and be willing and able to comply with the requirements of RevAssist®. * Able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients intolerant to aspirin may use warfarin or low molecular weight heparin). Exclusion Criteria: * Known Hepatitis B Ag positive, Hepatitis C positive patients. * Known HIV positive patients. * Patients with uncontrolled Autoimmune Hemolytic Anemia (AIHA) or autoimmune thrombocytopenia (ITP) * Patients with active fungal, bacterial, and/or viral infection * Patients with known hypersensitivity to Revlimid or thalidomide * Concurrent use of other anti-cancer agents or treatments * Patients with history of deep venous thrombus or pulmonary embolism * Patients who are at increased risk of thrombosis during treatment with Revlimid including those taking concurrent erythropoietin, darbepoetin or high-dose corticosteroids * Inability to provide informed consent. * Concurrent malignancy (excluding basal and squamous cell skin cancers). * Pregnant or breast-feeding females. (Lactating females must agree not to breast feed while taking Revlimid). * Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study. * Use of any other experimental drug or therapy within 28 days of baseline. * The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs. * Patients with a history of embolic events (e.g. TIA) from arrhythmia or peripheral arterial disease or of recent MI whether or not treated with anti-platelet drug.